Health Robotics Releases American "Live" Drug Database for its Second Generation Sterile Compounding Devices

BOZEN, Sud-Tirol, Italy, July 1, 2013 /PRNewswire/ --

In the wake of troubling and widespread events within the pharmacy outsourcing industry in the United States, Health Robotics recently decided to release to the pharmacy community^[1] at large, its North American Database of 330 supported and "Live" drug vials for automated sterile compounding, corresponding to 134 active pharmaceutical ingredients, including supported drug brands, available vial sizes, and drug vial concentrations from 58 drug manufacturers^[2].

Gaspar DeViedma, Health Robotics' Executive Vice President stated: "Considering the combined effects of the endemic drug shortages and the recent regulatory-related closures and product recalls of at least 50 pharmacy outsourced compounding centers^[3] in the first six months of 2013, there is no better time to make this drug database available as an Automation alternative to traditional compounding. The industry problems that were largely thought to be isolated to NECC and Ameridose in 2012 have just been proven to be widespread throughout the industry as widely reported in the news and through FDA inspections^[3]. With Health Robotics surpassing 100 American installations under contract within 2 years since commencing American operations, it is time to justly recognize the customers leading Health Robotics' User Group for their accomplishment in helping Health Robotics to create this wide-ranging drug database for IV Automation, including specific gravity, when not made available by some drug manufacturers."

About Health Robotics:

Founded in 2006 and now reaching 80% total IV Robots market share in the world [including over 90% the Oncology Robots global market], Health Robotics is the undisputed leading supplier of life-critical intravenous medication robots, providing mere than 400 hospital installations in 5 continents with the only fully-integrated Robotics-based technology, IV Workflow, and manual compounding software automation solutions. Health Robotics' second generation products [i.v.STATION, i.v.SOFT, and i.v.STATION ONCO] have been found [through scientific and peer-reviewed studies^[4],[5]] to greatly contribute to ease hospitals' growing pressures to improve patient safety^[4], increase throughput, and contain costs^[4]. Through the effective and efficient production of sterile, accurate, tamper-evident and ready-to-administer IVs, Health Robotics' medical devices and integrated workflow solutions help hospitals eliminate life-threatening drug^[4] and diluent^[4] exchange errors, improve drug potency^[5], decrease other medical mistakes and sterility risks, work more efficiently^[4], reduce waste and controlled substances' diversion, and diminish the gap between rising patient volume/acuity and scarce nursing, and pharmacy staff. For more information, please visit: http://www.health-robotics.com

1. http://www.health-robotics.com/en/solutions/drugdatabases/ [http://www.health-robotics.com/en/solutions/drugdatabases ]

2. The drug database for 58 medication manufacturers include: Abbott, Abraxis, Accord, Allos, Alza, American Regent, Amgen, Apotex, APP, Astellas, Astra Zaneca, Baxter, Bedford, Bristol Myers, Celgene, Cephalon, Cubist, Eisai, Forest, Genentech, Generamedix, Genzyme, Gilead, Greenstone, GSK, Hospira, IMS Limited, Ivax, Jansen, JHP, Lilly, Mayne, Merck, MGI, Millenium, Mylan, Nexus, Novaplus, NovoNordisk, Otsuka, Pfizer, Pharmacia, Roche, Sagent, Sandoz, Sanofi Aventis, Scios, Sicor, Teflaro, Teva, TMC, UCB, Watson Pharma, Westward, WG Critical Care, Wockhardt, Wyeth, and X-Gen.

3. http://www.fda.gov/AboutFDA/CentersOffices/OfficeofGlobalRegulatoryOperationsandPolicy/ORA/ORAElectronicReadingRoom/ucm340853.htm

4. Impact of Robotic Antineoplastic Preparation on Safety, Workflow, Costs. Seger, Churchill, Keohane, Belisle, Wong, Sylvester, Chesnick, Burdick, Wien, Cotugno, Bates, and Rothschild. Brigham & Women's Hospital, Massachusetts College of Pharmacy, and Harvard Medical School. Journal of Oncology Practice, Nov. 2012, Volume 8, number 6.

5. Validation of an automated method for compounding monoclonal antibody patient doses: case studies of Avastin®, Remicade®, and Herceptin®. Peters, Capelle, Arvinte, van de Garde. St. Antonius Hospital. mAbs January 2013, Volume 5, Issue 1.

For additional information, please contact:
Luisa Celeghin
[email protected]
+39-0403-498-468

SOURCE Health Robotics